T-cell Therapy Market is expected to Expand at a Compound Annual Growth Rate of 20.2% by 2028

T-cell Therapy Industry Overview

The global T-cell therapy market size is expected to reach USD 20.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 20.2% from 2021 to 2028. The milestone approvals of Kymriah and Yescarta along with the recent approval of Tecartus have bolstered the exponential revenue growth in the market.

The commercial launch of these innovative therapies across various regions has spurred the investment flow in this arena thereby driving the market. Cancer indications are the major investment targets for the key operating players. However, space is constantly expanding to include other indications such as viral infections, creating lucrative opportunities for the operating players.

T-cell Therapy Market Segmentation

Grand View Research has segmented the T-cell therapy market on the basis of modality, therapy type, indications, and regions:

Based on the Modality Insights, the market is segmented into Research and Commercialized

• The research segment dominated the market for T-cell therapy and accounted for more than 75.0% of revenue share in 2020 owing to the high number of products in the clinical development phase.
• The commercial base is expected to witness growth owing to the increasing regulatory approvals for commercial products across various countries as well as a rise in the number of medical centers implementing these therapies

Based on the Type Insights, the market is segmented into CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor-Infiltrating Lymphocytes (TIL)-based

• In 2020, CAR T-cell therapy segment dominated the market for T-cell therapy and accounted for the largest revenue share of 82.0% in 2020. This is owing to the exponential rise in the number of clinical trials for CAR-T therapies and the increasing involvement of key players in this arena.
• esides this, T-cell receptor-based therapies pegged the second position in the global space owing to their potential in the treatment of solid tumors. This segment is gaining significant attention for the treatment of melanoma.

Based on the Indication Insights, the market is segmented into Hematologic Malignancies, Solid Tumors, and Others

• In 2020, the hematologic malignancies segment dominated the market for T-cell therapy and accounted for a 49.0% revenue share.
• Given the high number of market entities entering the market and high fixed costs of autologous cell manufacturing, the segment is expected to witness high market competition in the near future.

T-cell Therapy Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

Key companies are undertaking various strategic initiatives to maintain their market position

Some prominent players in the global T-cell Therapy market include:

• Novartis AG
• Merck KGaA
• Gilead Sciences Inc.
• TCR2 Therapeutics Inc
• Bluebird Bio Inc.
• Sorrento Therapeutics
• Fate Therapeutics
• Pfizer Inc.
• Amgen
• Celgene Corporation

Order a free sample PDF of the T-cell Therapy Market Intelligence Study, published by Grand View Research.